



# Exploring Asia's investment megatrends: consumption, healthcare and net zero

By Nikko AM Asia ex-Japan Fund Co-Portfolio Managers Peter Monson and Eric Khaw 11 July 2023

# **Key Takeaways**



- Asia's demographic dividend will ensure the region accounts for half of global consumption within the next decade.
- A decade of investment into Asia's healthcare needs has promoted innovation in biosciences and the expansion of digital health technologies within rural and previously underserved areas.
- Asia is leading the pack in providing for global decarbonisation and securing substantial rewards – it already dominates in battery cell and related component manufacturing, in the solar value chain and is pushing ahead in the development of climate-related innovations.

Right now, three megatrends are widely prevalent across Asia which look like significant drivers of investment growth for many years to come. These megatrends are consumption, healthcare and the net zero transition.

## The rise of the Asian consumer

Asia's immense population makes it the most significant consumer market in the world. Moreover, the rapid economic growth of many Asian countries in recent years has helped to significantly increase its population's disposable income from a much lower base. According to Euromonitor's 2022 Income and Expenditure in Asia Pacific report, total disposable income in the Asia-Pacific region is set to more than double in real terms over the 2021-2040 period, faster than in any other region, although it will still be among the lowest globally.\(^1\) Consumers in Asia are expected to account for half of global consumption growth within the next decade. Many countries in Asia are already benefitting hugely from their 'demographic dividend' – the boost to consumption and economic productivity driven by a young and growing population.

<sup>&</sup>lt;sup>1</sup> https://www.euromonitor.com/income-and-expenditure-in-asia-pacific/report



Reflecting this demographic dividend, Asian consumption has experienced a paradigm shift evidenced by the rise of domestic brands, the increasing prominence of lower-tier cities, and a growing awareness of environmental and social issues among consumers. The pandemic has been instrumental in deepening and accelerating these changes. No wonder then, McKinsey calls Asia "a \$10 trillion consumption growth opportunity".<sup>2</sup>

# Asia's healthcare story

Across Asia, healthcare innovation and investment are borne from a critical need. Asia is home to more than 4.5 billion people, and its growing and ageing population demands access to better healthcare services, as well as innovative, affordable and accessible medicines. The imperative for healthcare investment in Asia has only accelerated post-pandemic. But Asia's healthcare industry today is where its technology industry was in the 2000s, and more than a decade of investment is now bearing fruit.


Across the Asia-Pacific region, governments have encouraged private sector investment and public-private partnerships, introduced new regulations and standards to encourage innovation in biomedical sciences and ensure a high standard of care, and promoted digital health technologies to serve rural and previously underserved areas.

Moreover, extensive and relentless research and development (R&D) efforts – coupled with major advances in medical technology – have enabled the development of new treatment modalities, greatly improving clinical outcomes. In addition, Asia's key role in the global manufacturing supply chain of medicines, as well as the rise in demand for outsourced research, development and manufacturing services, uniquely positions the region to capitalise on the growth opportunities in healthcare.

#### **Drug manufacturing and ingredients**

Until the 1990s, the West and Japan produced 90% of the active chemicals used in drug manufacturing, also known as 'active pharmaceutical ingredients' (APIs). Such ingredients are sourced from chemical suppliers and formulated into a final dosage form – such as a tablet, capsule, or injection. However, Asia's decade-long investment in the pharmaceutical industry, and its increasing ability to manufacture consistent, high-quality APIs, meant that by 2020, the region was producing more than 60% of the world's APIs. China alone accounted for the bulk of exports of several key pharmaceutical raw materials, and – according to Nikkei Asia – was by then already playing "an indispensable role in the supply chain for antibiotics and vitamins".<sup>3</sup>

Figure 1 - China's share of global exports of key pharmaceutical ingredients in 2020, by volume



Source: Nikkei Asia, Trade Map, data may contain chemical compounds for other uses

But more significant developments are taking place throughout Asia, driven by the universal need for better medicines. A big turning point for the healthcare industry as a whole – providing confirmation that healthcare in Asia is an investment megatrend – is that Asian companies are now developing potentially first-to-market, globally competitive and innovative drugs.

### The transition to net zero

Net zero is a global challenge that requires a united response. All countries and regions need to decarbonise, but there are substantial rewards on the table for those most capable of driving the push for global decarbonisation. So,

<sup>&</sup>lt;sup>2</sup> https://www.mckinsey.com/featured-insights/future-of-asia/videos/driving-asias-10-trillion-consumption-growth-opportunity

<sup>&</sup>lt;sup>3</sup> https://asia.nikkei.com/static/vdata/infographics/chinavaccine-3/



who is building the materials and equipment needed to realise the world's net zero ambitions? The answer, both now and well into the future, is Asia.

Take transportation as an example. All forms of transportation – including road, air, rail, sea and others – contributes approximately 21% of annual global  $CO_2$  emissions.<sup>4</sup> The transition towards a clean transport infrastructure and greener vehicles – replacing internal combustion engine vehicles with electric vehicles and those powered by hydrogen fuel cells – would make a significant contribution towards achieving net zero.

Asia leads the world in battery cell and related component manufacturing. Battery storage and grid-level electricity storage rely on metals such as lithium, cobalt or nickel. Again, the supply chain for all of these depends heavily on either Asia or the emerging markets. Electric vehicle (EV) sales have caused demand to grow exponentially and it's looking increasingly unlikely that Asia's leading manufacturers will be dislodged as economies of scale become more entrenched. The lithium-ion battery market is expected to grow from USD 57 billion in 2020 to USD 200 billion by 2027<sup>5</sup>, and the key components are currently supplied from China, South Korea and Japan.

Material processing Mining Cell components Battery cells **EVs** 100% 75% 50% 25% 0% Li Ni Со Gr Li Ni Со Gr Cathode Anode Battery production EV production Europe United States Japan Korea DRC Indonesia Russia

Figure 2 – Geographical distribution of the global EV battery supply chain

Notes: Li = lithium; Ni = nickel; Co = cobalt; Gr = graphite; DRC = Democratic Republic of Congo. Geographical breakdown refers to the country where the production occurs. Mining is based on production data. Material processing is based on refining production capacity data. Cell component production is based on cathode and anode material production capacity data. Battery

cell production is based on battery cell production capacity data. EV production is based on EV production data. Although Indonesia produces around 40% of total nickel, little of this is currently used in the EV battery supply chain. The largest Class 1 batterygrade nickel producers are Russia, Canada and Australia.

Source: IEA analysis based on: EV Volumes; US Geological Survey (2022); Benchmark Mineral Intelligence; Bloomberg NEF.

China, in particular, is charging ahead in its efforts to develop its renewable energy capacity. While remaining the world's biggest user of coal, a recent study by Global Energy Monitor (GEM) forecast that China will more than double its large-scale solar and wind capacity over the next few years. This would see the nation meet its 2020 commitment to install over 1,200 gigawatts of solar and wind power five years ahead of schedule.<sup>6</sup>

In addition, Asia continues to move forward in terms of research and development on climate-related issues. According to McKinsey, Japan, South Korea, China and India are in the top quartile for the number of patent filings relating to climate-change mitigation, while South Korea, Japan, China and Singapore are all in the top quartile of countries for spending on R&D as a percentage of GDP.<sup>7</sup>

These three investment megatrends – consumption healthcare, and net zero initiatives – demonstrate the direction of travel for Asia. What's more, due to their domestic focus these trends are more geopolitically insulated than other more export-orientated sectors in Asia.

If you believe these megatrends offer significant growth potential, it makes sense to consider the opportunity to embrace the future direction of travel. For more information on Asia's investment megatrends, please download Nikko AM's investment guide: <u>Harnessing change in Asia</u>.

<sup>&</sup>lt;sup>4</sup> https://ourworldindata.org/co2-emissions-from-transport

<sup>&</sup>lt;sup>5</sup> Lithium-Ion Battery Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)

<sup>&</sup>lt;sup>6</sup> Climate change: China's green power surge offers hope on warming - BBC News

 $<sup>{\</sup>it \rat https://www.mckinsey.com/capabilities/sustainability/our-insights/the-net-zero-transition-what-it-would-cost-what-it-could-bring}$ 



#### If you have any questions on this report, please contact:

**Nikko AM team in Europe** Email: EMEAenquiries@nikkoam.com

**Important information:** This document is prepared by Nikko Asset Management Co., Ltd. and/or its affiliates (Nikko AM) and is for distribution only under such circumstances as may be permitted by applicable laws. This document does not constitute personal investment advice or a personal recommendation and it does not consider in any way the objectives, financial situation or needs of any recipients. All recipients are recommended to consult with their independent tax, financial and legal advisers prior to any investment.

This document is for information purposes only and is not intended to be an offer, or a solicitation of an offer, to buy or sell any investments or participate in any trading strategy. Moreover, the information in this document will not affect Nikko AM's investment strategy in any way. The information and opinions in this document have been derived from or reached from sources believed in good faith to be reliable but have not been independently verified. Nikko AM makes no guarantee, representation or warranty, express or implied, and accepts no responsibility or liability for the accuracy or completeness of this document. No reliance should be placed on any assumptions, forecasts, projections, estimates or prospects contained within this document. This document should not be regarded by recipients as a substitute for the exercise of their own judgment. Opinions stated in this document may change without notice.

In any investment, past performance is neither an indication nor guarantee of future performance and a loss of capital may occur. Estimates of future performance are based on assumptions that may not be realised. Investors should be able to withstand the loss of any principal investment. The mention of individual securities, sectors, regions or countries within this document does not imply a recommendation to buy or sell.

Nikko AM accepts no liability whatsoever for any loss or damage of any kind arising out of the use of all or any part of this document, provided that nothing herein excludes or restricts any liability of Nikko AM under applicable regulatory rules or requirements.

All information contained in this document is solely for the attention and use of the intended recipients. Any use beyond that intended by Nikko AM is strictly prohibited.

Japan: The information contained in this document pertaining specifically to the investment products is not directed at persons in Japan nor is it intended for distribution to persons in Japan. Registration Number: Director of the Kanto Local Finance Bureau (Financial Instruments firms) No. 368 Member Associations: The Investment Trusts Association, Japan/Japan Investment Advisers Association.

**United Kingdom**: This document is communicated by Nikko Asset Management Europe Ltd, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority (the FCA) (FRN 122084). This document constitutes a financial promotion for the purposes of the Financial Services and Markets Act 2000 (as amended) (FSMA) and the rules of the FCA in the United Kingdom, and is directed at professional clients as defined in the FCA Handbook of Rules and Guidance.

Luxembourg and Germany: This document is communicated by Nikko Asset Management Luxembourg S.A., which is authorised and regulated in the Grand Duchy of Luxembourg by the Commission de Surveillance du Secteur Financier (the CSSF) as a management company authorised under Chapter 15 of the Law of 17 December 2010 (No S00000717) and as an alternative investment fund manager according to the Law of 12 July 2013 (No. A00002630).

**United States:** This document may not be duplicated, quoted, discussed or otherwise shared without prior consent. Any offering or distribution of a Fund in the United States may only be conducted via a licensed and registered broker-dealer or a duly qualified entity. Nikko Asset Management Americas, Inc. is a United States Registered Investment Adviser.

Singapore: This document is for information to institutional investors as defined in the Securities and Futures Act (Chapter 289), and intermediaries only. Nikko Asset Management Asia Limited (Co. Reg. No. 198202562H) is regulated by the Monetary Authority of Singapore.

Hong Kong: This document is for information to professional investors as defined in the Securities and Futures Ordinance, and intermediaries only. The contents of this document have not been reviewed by the Securities and Futures Commission or any regulatory authority in Hong Kong. Nikko Asset Management Hong Kong Limited is a licensed corporation in Hong Kong.

**New Zealand:** This document is issued in New Zealand by Nikko Asset Management New Zealand Limited (Company No. 606057, FSP22562). It is for the use of wholesale clients, researchers, licensed financial advisers and their authorised representatives only.

Kingdom of Bahrain: The document has not been approved by the Central Bank of Bahrain which takes no responsibility for its contents. No offer to the public to purchase the Strategy will be made in the Kingdom of Bahrain and this document is intended to be read by the addressee only and must not be passed to, issued to, or shown to the public generally.



**Kuwait:** This document is not for general circulation to the public in Kuwait. The Strategy has not been licensed for offering in Kuwait by the Kuwaiti Capital Markets Authority or any other relevant Kuwaiti government agency. The offering of the Strategy in Kuwait on the basis a private placement or public offering is, therefore, restricted in accordance with Decree Law No. 7 of 2010 and the bylaws thereto (as amended). No private or public offering of the Strategy is being made in Kuwait, and no agreement relating to the sale of the Strategy will be concluded in Kuwait. No marketing or solicitation or inducement activities are being used to offer or market the Strategy in Kuwait.

Kingdom of Saudi Arabia: This document is communicated by Nikko Asset Management Europe Ltd (Nikko AME), which is authorised and regulated by the Financial Services and Markets Act 2000 (as amended) (FSMA) and the rules of the Financial Conduct Authority (the FCA) in the United Kingdom (the FCA Rules). This document should not be reproduced, redistributed, or sent directly or indirectly to any other party or published in full or in part for any purpose whatsoever without a prior written permission from Nikko AME.

This document does not constitute investment advice or a personal recommendation and does not consider in any way the suitability or appropriateness of the subject matter for the individual circumstances of any recipient. In providing a person with this document, Nikko AME is not treating that person as a client for the purposes of the FCA Rules other than those relating to financial promotion and that person will not therefore benefit from any protections that would be available to such clients.

Nikko AME and its associates and/or its or their officers, directors or employees may have or have had positions or material interests, may at any time make purchases and/or sales as principal or agent, may provide or have provided corporate finance services to issuers or may provide or have provided significant advice or investment services in any investments referred to in this document or in related investments. Relevant confidential information, if any, known within any company in the Nikko AM group or Sumitomo Mitsui Trust Holdings group and not available to Nikko AME because of regulations or internal procedure is not reflected in this document. The investments mentioned in this document may not be eligible for sale in some states or countries, and they may not be suitable for all types of investors.

Oman: The information contained in this document nether constitutes a public offer of securities in the Sultanate of Oman as contemplated by the Commercial companies law of Oman (Royal decree 4/74) or the Capital Markets Law of Oman (Royal Decree80/98, nor does it constitute an offer to sell, or the solicitation of any offer to buy non-Omani securities in the Sultanate of Oman as contemplated by Article 139 of the Executive Regulations to the Capital Market law (issued by Decision No. 1/2009). This document is not intended to lead to the conclusion of any contract of whatsoever nature within the territory of the Sultanate of Oman.

**Qatar (excluding QFC):** The Strategies are only being offered to a limited number of investors who are willing and able to conduct an independent investigation of the risks involved in an investment in such Strategies. The document does not constitute an offer to the public and should not be reproduced, redistributed, or sent directly or indirectly to any other party or published in full or in part for any purpose whatsoever without a prior written permission from Nikko Asset Management Europe Ltd (Nikko AME). No transaction will be concluded in your jurisdiction and any inquiries regarding the Strategies should be made to Nikko AME.

United Arab Emirates (excluding DIFC): This document and the information contained herein, do not constitute, and is not intended to constitute, a public offer of securities in the United Arab Emirates and accordingly should not be construed as such. The Strategy is only being offered to a limited number of investors in the UAE who are (a) willing and able to conduct an independent investigation of the risks involved in an investment in such Strategy, and (b) upon their specific request.

The Strategy has not been approved by or licensed or registered with the UAE Central Bank, the Securities and Commodities Authority or any other relevant licensing authorities or governmental agencies in the UAE. This document is for the use of the named addressee only and should not be given or shown to any other person (other than employees, agents or consultants in connection with the addressee's consideration thereof).

No transaction will be concluded in the UAE and any inquiries regarding the Strategy should be made to Nikko Asset Management Europe Ltd.

Republic of Korea: This document is being provided for general information purposes only, and shall not, and under no circumstances is, to be construed as, an offering of financial investment products or services. Nikko AM is not making any representation with respect to the eligibility of any person to acquire any financial investment product or service. The offering and sale of any financial investment product is subject to the applicable regulations of the Republic of Korea. Any interests in a fund or collective investment scheme shall be sold after such fund is registered under the private placement registration regime in accordance with the applicable regulations of the Republic of Korea, and the offering of such registered fund shall be conducted only through a locally licensed distributor.